CRISPR Therapeutics (CRSP) PT Lowered to $122 at Needham & Company
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $53.99 -0.15%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Needham & Company analyst Gil Blum lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $122.00 (from $170.00) while maintaining a Buy rating.
You May Also Be Interested In
- Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
- Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
- Toei co Ltd (9605:JP) PT Raised to JPY6,100 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
